FDA Highlights Programs for Innovators at ACR DSI Summit
The FDA joined the ACR®️ Data Science Summit June 9 to give an update about its Total Product Life Cycle Advisory Program.
Read moreCMS announced temporary reassignment of coronary CT angiography (CCTA) codes 75572–75574 in the 2025 Hospital Outpatient Prospective Payment System (OPPS) final rule. The change moved these codes from APC 5571 (Level 1 Imaging with Contrast) to APC 5572 (Level 2 Imaging with Contrast). This resulted in a significant technical fee increase, from $175 in 2024 to $357 in 2025, a 104% boost. These codes remain in APC 5572 in 2026, but only on a provisional basis. CMS made the reassignment saying the reclassification better reflects the resource intensity and clinical value of CCTA services.
ACR®, along with the American College of Cardiology and the Society of Cardiovascular Computed Tomography (SCCT), stress the importance of updating their charge masters for CCTA studies as CMS could revert reimbursement to the lower APC classification. The associations developed guidance [CS1.1]with action steps to help hospitals update their charge masters.
This change follows CMS’s removal of a restrictive Return to Provider Edit, granting hospitals flexibility to update cost reports and revenue codes. The reclassification better reflects the resource intensity and clinical value of CCTA services.
If you have questions or would like more information, contact Kimberly Greck, ACR Senior Economic Policy Analyst.
FDA Highlights Programs for Innovators at ACR DSI Summit
The FDA joined the ACR®️ Data Science Summit June 9 to give an update about its Total Product Life Cycle Advisory Program.
Read moreLower Fee Now in Effect to File No Surprises Act Disputes
Federal agencies released a final rule that updates the No Surprises Act independent dispute resolution process. The rule lowers the IDR administrative or filing fee from $115 to $15.
Read moreACR Urges Funding for NIH All of Us Program
ACR urges Congress to provide dedicated funding for NIH’s All of Us Research Program, a leader in precision medicine technologies and a valuable tool for researchers.
Read more